Literature DB >> 3918340

Kinetic evaluation of four Factor VIII concentrates by model-independent methods.

M Matucci, A Messori, G Donati-Cori, G Longo, S Vannini, M Morfini, E Tendi, P L Rossi-Ferrini.   

Abstract

Single-dose kinetics of 4 Factor VIII concentrates (Kryobulin, Hemofil T, Koate, cryoprecipitate) were studied in 41 patients with haemophilia-A. Model-independent methods were adopted for calculating the kinetic parameters (area under the curve, clearance, area under the moment curve, mean residence time, volume of distribution at steady-state). No substantial difference was observed in the kinetic characteristics of the 4 Factor VIII concentrates. A considerable interindividual variability of the calculated kinetic parameters was demonstrated for all concentrates. Our findings support the need to individualize Factor VIII dosage.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918340     DOI: 10.1111/j.1600-0609.1985.tb00739.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  10 in total

1.  Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs.

Authors:  A Messori; G Longo; M Morfini; S Cinotti; E Filimberti; G Giustarini; P Rossi Ferrini
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

4.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

5.  Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.

Authors:  S Björkman; M Carlsson; E Berntorp; P Stenberg
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.

Authors:  A Messori; G Longo; M Matucci; M Morfini; P L Ferrini
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

7.  Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

Authors:  Sven Björkman; Anna Folkesson; Siv Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2009-06-26       Impact factor: 2.953

Review 8.  Pediatric Dosing and Body Size in Biotherapeutics.

Authors:  Rong Shi; Hartmut Derendorf
Journal:  Pharmaceutics       Date:  2010-12-16       Impact factor: 6.321

Review 9.  The History of Clotting Factor Concentrates Pharmacokinetics.

Authors:  Massimo Morfini
Journal:  J Clin Med       Date:  2017-03-20       Impact factor: 4.241

10.  A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.

Authors:  Victor S Blanchette; Laura Zunino; Viviane Grassmann; Chris Barnes; Manuel D Carcao; Julie Curtin; Shannon Jackson; Liane Khoo; Vladimir Komrska; David Lillicrap; Massimo Morfini; Gabriela Romanova; Derek Stephens; Ester Zapotocka; Margaret L Rand; Jan Blatny
Journal:  Thromb Haemost       Date:  2021-04-14       Impact factor: 6.681

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.